Blood-based Shield test detects 83% of colorectal cancers but only 13% of advanced precancerous lesions

▪ SCREENING

In the large-scale ECLIPSE study of average-risk individuals, the Shield cell-free DNA assay showed 83.1% sensitivity for colorectal cancer but only 13.2% sensitivity for advanced precancerous lesions, highlighting a key limitation of blood-based screening. (Diagnostics)